Biotech Values

[DewDiligence]

EQRX -31% on sugemalimab program discontinuation:

https://finance.yahoo.com/news/eqrx-provides-portfolio-u-commercial-120000860.html

No commercially viable path for sugemalimab plus chemotherapy for Stage IV NSCLC in the U.S.: The Company believes based on recent interactions with the FDA that only the final overall survival results of a second Phase 3 trial comparing sugemalimab with approved PD(L)1 therapy would support a U.S. filing for a Stage IV NSCLC indication, and that interim study readouts of such a trial would not be supportive of a filing based on the GEMSTONE-302 study. As such, EQRx plans to discontinue future U.S. development efforts for sugemalimab plus chemotherapy in this indication.